HK1204944A1 - '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和抗抑鬱藥劑的藥物組合物 - Google Patents

'- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和抗抑鬱藥劑的藥物組合物

Info

Publication number
HK1204944A1
HK1204944A1 HK15105575.5A HK15105575A HK1204944A1 HK 1204944 A1 HK1204944 A1 HK 1204944A1 HK 15105575 A HK15105575 A HK 15105575A HK 1204944 A1 HK1204944 A1 HK 1204944A1
Authority
HK
Hong Kong
Prior art keywords
pyrano
antidepressants
indol
spiro
dihydro
Prior art date
Application number
HK15105575.5A
Other languages
English (en)
Inventor
Stefanie Frosch
Klaus Linz
Thomas Christoph
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of HK1204944A1 publication Critical patent/HK1204944A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15105575.5A 2012-05-18 2015-06-11 '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和抗抑鬱藥劑的藥物組合物 HK1204944A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003937 2012-05-18
PCT/EP2013/001464 WO2013170965A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and antidepressants

Publications (1)

Publication Number Publication Date
HK1204944A1 true HK1204944A1 (zh) 2015-12-11

Family

ID=48446243

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105575.5A HK1204944A1 (zh) 2012-05-18 2015-06-11 '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和抗抑鬱藥劑的藥物組合物

Country Status (23)

Country Link
US (2) US20130310385A1 (zh)
EP (1) EP2849744B1 (zh)
JP (1) JP6116672B2 (zh)
CN (1) CN104271131A (zh)
AU (1) AU2013262071B2 (zh)
BR (1) BR112014028562A2 (zh)
CA (1) CA2873634A1 (zh)
CY (1) CY1119825T1 (zh)
DK (1) DK2849744T3 (zh)
EA (1) EA027268B1 (zh)
ES (1) ES2660461T3 (zh)
HK (1) HK1204944A1 (zh)
HR (1) HRP20171922T1 (zh)
HU (1) HUE037746T2 (zh)
IL (1) IL235657B (zh)
LT (1) LT2849744T (zh)
MX (1) MX354684B (zh)
NO (1) NO2849744T3 (zh)
PL (1) PL2849744T3 (zh)
PT (1) PT2849744T (zh)
RS (1) RS56856B1 (zh)
SI (1) SI2849744T1 (zh)
WO (1) WO2013170965A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3247352T3 (da) 2015-01-23 2020-09-07 Gruenenthal Gmbh Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584720A (ja) 1981-06-26 1983-01-11 ザ・アツプジヨン・カンパニ− 鎮痛用医薬組成物
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
EP0189788B1 (de) 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
CA2058754C (en) 1989-05-22 2002-02-19 Hubertus L. Regtop Divalent metal salts of indomethacin
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1993000895A1 (en) 1991-07-04 1993-01-21 Taisho Pharmaceutical Co., Ltd. Analgesic
JPH05221857A (ja) 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
JPH08511522A (ja) 1993-06-07 1996-12-03 メルク エンド カンパニー インコーポレーテッド ニューロキニンアンタゴニストとしてのスピロ置換アザ環
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US20030056896A1 (en) 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
CA2343148C (en) 1998-09-10 2005-11-15 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
WO2000028980A2 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
WO2002026714A1 (fr) 2000-09-27 2002-04-04 Takeda Chemical Industries, Ltd. Composes spiraniques
DE50104197D1 (de) 2000-12-28 2004-11-25 Fresenius Kabi Austria Gmbh Gr Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
WO2003064425A1 (en) 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
ES2286177T3 (es) 2002-06-17 2007-12-01 Chiesi Farmaceutici S.P.A. Procedimiento para la preparacion de piroxicam: compuestos de inclusion de betaciclodextrina.
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DK1567164T3 (da) 2002-11-26 2009-05-18 Alexza Pharmaceuticals Inc Anvendelse af loxapin til fremstilling af et lægemiddel til behandling af smerte
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CN1245379C (zh) 2003-10-30 2006-03-15 曹桂东 加巴喷丁的制法
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
GB0412878D0 (en) * 2004-06-09 2004-07-14 Pfizer Ltd Use
KR20070029740A (ko) * 2004-06-09 2007-03-14 화이자 인코포레이티드 통증 치료를 위한 레복세틴의 용도
JP2008543827A (ja) 2005-06-17 2008-12-04 ファイザー株式会社 ＯＲＬ１受容体拮抗薬としてのα−（アリール−またはヘテロアリール−メチル）−βピペリジノプロパンアミド化合物
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
PT2012764E (pt) 2006-04-28 2011-02-02 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1- etil-2-metilpropil)fenol e paracetamol
ES2358763T3 (es) 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
US20080014264A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
CN101147735A (zh) 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
JP2008106028A (ja) 2006-10-26 2008-05-08 Boehringer Ingelheim Internatl Gmbh 慢性疼痛の治療におけるフリバンセリンの使用
DE102006056458A1 (de) 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
US20080153874A1 (en) 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2008108639A1 (en) 2007-03-08 2008-09-12 Avantium Holding B.V. Co-crystalline forms of carbamazepine
EP1977744A1 (en) 2007-04-03 2008-10-08 Chemo Ibérica, S.A. Polymorphic Form alpha of (S)-Pregabalin and process for its preparation
EP2207569B1 (en) 2007-10-09 2013-03-27 Merck Patent GmbH Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
DK2244703T3 (da) 2007-12-21 2011-12-05 Horizon Pharma Ag Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
US20090298947A1 (en) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
PE20110305A1 (es) 2008-09-05 2011-06-15 Gruenenthal Chemie Combinacion farmaceutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid
AR073277A1 (es) 2008-09-05 2010-10-28 Gruenenthal Gmbh Combinacion farmaceutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol, y uso
KR101851120B1 (ko) 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
WO2012016695A2 (en) * 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
BR112013002734A2 (pt) * 2010-08-04 2016-06-07 Gruenenthal Gmbh uso de agente farmacologicamente ativo e forma de dosagem farmacêutica
RU2589830C2 (ru) * 2010-08-04 2016-07-10 Грюненталь Гмбх ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative

Also Published As

Publication number Publication date
SI2849744T1 (en) 2018-01-31
HUE037746T2 (hu) 2018-09-28
US10328055B2 (en) 2019-06-25
IL235657B (en) 2018-08-30
US20130310385A1 (en) 2013-11-21
MX2014012859A (es) 2015-01-19
AU2013262071A1 (en) 2015-01-22
LT2849744T (lt) 2018-02-26
BR112014028562A2 (pt) 2017-06-27
NO2849744T3 (zh) 2018-04-21
EA201401269A1 (ru) 2016-05-31
JP6116672B2 (ja) 2017-04-19
DK2849744T3 (en) 2018-01-22
RS56856B1 (sr) 2018-04-30
IL235657A0 (en) 2015-01-29
EA027268B1 (ru) 2017-07-31
JP2015520154A (ja) 2015-07-16
CY1119825T1 (el) 2018-06-27
PT2849744T (pt) 2018-02-28
AU2013262071B2 (en) 2018-01-18
CA2873634A1 (en) 2013-11-21
MX354684B (es) 2018-03-15
WO2013170965A1 (en) 2013-11-21
EP2849744B1 (en) 2017-11-22
CN104271131A (zh) 2015-01-07
EP2849744A1 (en) 2015-03-25
HRP20171922T1 (hr) 2018-02-09
US20170065560A1 (en) 2017-03-09
PL2849744T3 (pl) 2018-06-29
ES2660461T3 (es) 2018-03-22

Similar Documents

Publication Publication Date Title
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
HK1204992A1 (zh) 含有舒尼替尼的局部眼科藥物組合物
HK1204937A1 (zh) '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和抗驚厥劑的藥物組合物
HK1204942A1 (zh) '- '- '- 包含 ‘-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和丙酸衍生物的藥物組合物
HK1204943A1 (zh) '- '- '- 包含 '-氟- -二甲基- -苯基- '， '-二氫- -螺 環己烷- '-吡喃並 吲哚 -胺和加巴噴丁類化合物的藥物組合物
HK1204938A1 (zh) '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和 的藥物組合物
HK1204944A1 (zh) '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和抗抑鬱藥劑的藥物組合物
HK1204939A1 (zh) '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和奧昔康類化合物的藥物組合物
HK1199258A1 (zh) '- '- '- '-氟代- -二甲基- -苯基- '， '-二氫- -螺環- 環己烷- '-吡喃並 吲哚基 -鹽酸胺的固體形式
HK1204940A1 (zh) '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和對乙醯氨基酚或丙帕他莫的藥物組合物
HK1204941A1 (zh) '- '- '- 包含 ’-氟- -二甲基- -苯基- ’， ’-二氫- -螺 環己烷- ’-吡喃並 吲哚 -胺和水楊酸組分的藥物組合物
EP2930175A4 (en) NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220515